| Literature DB >> 28814850 |
Erika Zavaglia Kabbach1, Adriana Mazzuco1, Audrey Borghi-Silva1, Ramona Cabiddu1, Aline Galvão Agnoleto1, Jessica Fernanda Barbosa1, Luiz Carlos Soares de Carvalho Junior1, Renata Gonçalves Mendes1.
Abstract
BACKGROUND: Cardiac autonomic modulation (CAM) is impaired in patients with stable COPD. Exacerbation aggravates the patients' health status and functional capacity. While the clinical and functional effects of exacerbation are known, no studies investigated CAM during exacerbation and whether there is a relationship between CAM and functional capacity and dyspnea.Entities:
Keywords: autonomic nervous system; functional capacity; hospitalization; pulmonary disease
Mesh:
Substances:
Year: 2017 PMID: 28814850 PMCID: PMC5546179 DOI: 10.2147/COPD.S134498
Source DB: PubMed Journal: Int J Chron Obstruct Pulmon Dis ISSN: 1176-9106
Baseline patients’ characteristics
| Clinical data | GAE (n=16) | GSta (n=16) | |
|---|---|---|---|
| Age, years | 70.3±10.1 | 66.3±8.4 | 0.2 |
| Gender, male/female (n) | 11/5 | 16/0 | 0.1 |
| BMI, kg/m2 | 25.0±5.8 | 24.7±4.2 | 0.9 |
| Exacerbation, n/year | 1.9±1.8 | 1.0±0.9 | 0.2 |
| mMRC | 2.5 (1.25–3) | 1 (1–2) | 0.04 |
| Smoking, never/ex/current | 1 (6.3)/13 (81.3)/2 (12.5) | 0/16 (100)/0 | 0.03 |
| Pack-years | 41.0±27.6 | 48.0±26.9 | 0.5 |
| Clinical parameters | |||
| HR, bpm | 78.1±13.5 | 81.2±9.9 | 0.4 |
| RR, rpm | 21.6±2.2 | 18.8±2.9 | 0.006 |
| SBP, mmHg | 118.1±13.7 | 123.2±17.2 | 0.36 |
| DBP, mmHg | 75.6±8.1 | 75.8±9.0 | 1.0 |
| SpO2, % | 93.5±3.2 | 93.3±2.3 | 0.08 |
| Lung function | |||
| Forced vital capacity, % predicted | 69.9±16.9 | 92.6±21.1 | 0.005 |
| FEV1, % predicted | 40.4±12.4 | 53.9±19.7 | 0.04 |
| FEV1/forced vital capacity | 45.0±12.8 | 56.5±14.0 | 0.03 |
| MIP (cmH2O/% predicted) | −30.7±15.6/28±18 | −92.4±32.3/92±30 | <0.001 |
| MEP (cmH2O/% predicted) | 54.5±20.5/46±21 | 125.8±30.4/112±34 | <0.001 |
| PaO2, mmHg | 91.3±35 | 70.2±6.3 | 0.01 |
| PaCO2, mmHg | 40.8±7.2 | 37.1±4.7 | 0.1 |
| Main comorbidities, n (%) | |||
| Hypertension | 11 (68.8) | 9 (56.3) | 0.1 |
| Type 2 diabetes | 3 (18.8) | 3 (18.8) | 1.0 |
| Stroke | 3 (18.8) | 0 | 0.01 |
| Alcoholism, ex/current | 2 (12.5)/1 (6.3) | 5 (31.3)/0 | 0.1 |
| Therapies, n (%) | |||
| laBa | – | 1 (6.3) | |
| laBa + ICs | – | 5 (31.3) | |
| laBa + ICs + laMa | – | 9 (56.3) | |
| laBa + laMa | – | 1 (6.3) | |
| saBa + ICs | 4 (25) | – | |
| saBa + ICs + saMa | 10 (62.5) | – | |
| saBa + saMa | 2 (12.5) | – | |
Note: Data are presented as mean ± SD or median (interquartile).
Abbreviations: BMI, body mass index; mMRC, modified Medical Research Council; HR, heart rate; RR, respiratory rate; SBP, systolic brachial pressure; DBP, diastolic brachial pressure; FEV1, forced expiratory volume in 1 second; MIP, maximal inspiratory pressure; MEP, maximal expiratory pressure; laBa, long-acting beta-2 agonist; ICs, inhaled corticosteroids; laMa, long-acting anticholinergics; saBa, short-acting beta-2 agonist; saMa, short-acting anticholinergics; SD, standard deviation; GAE, acute exacerbation COPD group; GSta, stable COPD group.
Figure 1PSD for (A) a patient from the exacerbated group and (B) a patient from the stable group.
Abbreviations: PSD, power spectral density; GAE, acute exacerbation COPD group; GSta, stable COPD group.
Figure 2Poincare plots for (A) a patient from the exacerbated group and (B) a patient from the stable group.
Abbreviations: RRi, R-wave peak detection intervals; SD1, standard deviation measuring the dispersion of points in the plot perpendicular to the line of identity; SD2, standard deviation measuring the dispersion of points along the line of identity; GAE, acute exacerbation COPD group; GSta, stable COPD group.
HRV values
| HRV index | GAE | GSta | |
|---|---|---|---|
| Time domain | |||
| Mean RRi, ms | 721.6±106.9 | 736.8±133.5 | 0.72 |
| STD RRi, ms | 19.3±6.5 | 14.3±12.5 | 0.007 |
| RMSSD, ms | 17.8±5.6 | 11.7±9.5 | 0.008 |
| RRi tri | 5.2±1.7 | 4.0±3.0 | 0.01 |
| TINN, ms | 88.7±26.9 | 70.6±62.2 | 0.01 |
| Frequency domain | |||
| LF, ms2 | 203.0±210.7 | 101.8±169.7 | 0.01 |
| HF, ms2 | 111.3±74.9 | 45.6±80.7 | 0.002 |
| LF/HF | 2.5±2.1 | 2.3±2.0 | 0.6 |
| Non-linear analysis | |||
| SD1 | 12.7±3.9 | 8.3±6.7 | 0.007 |
| SD2 | 30.4±14.8 | 16.2±12.5 | <0.001 |
| ApEn | 0.9±0.07 | 1.0±0.06 | 0.002 |
| SampEn | 1.4±0.32 | 1.7±0.3 | 0.007 |
Abbreviations: HRV, heart rate variability; RRi, R-wave peak detection intervals; STD RRi, standard deviation of RRi; RMSSD, root mean square of successive differences; RRi tri, triangular index; TINN, triangular interpolation of RRi; LF, low frequency; HF, high frequency; SD1, beat-to-beat variability; SD2, standard deviation of long-term variability; ApEn, approximate entropy; SampEn, sample entropy; GAE, acute exacerbation COPD group; GSta, stable COPD group.
Figure 3Correlations between HRV indices to standard and functional capacity.
Notes: Data are presented as the correlation coefficient (r) and P<0.05. HF (nu): high frequency expressed in normalized units; handgrip strength expressed in kilogram-force (kgf).
Abbreviations: HRV, heart rate variability; HF, high frequency.